Stoke Therapeutics, Inc. (STOK) stock
Close on Nov 12, 2026Market cap $1.69BP/E –Yield –
Stoke Therapeutics, Inc. saw revenue fall 86.2% to $27.59M over the twelve months to Jun 30, 2026. Operating income fell 654.5% to -$223.38M, moving the operating margin from 20.2% to -809.7%. Free cash flow was -$180.68M, down 395.5% from a year earlier. At the latest close the market valued the company at $1.69B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.69B
- P/E ratio
- –
- Price to sales
- 61.28
- Price to book
- 4.89
- Dividend yield
- –
- Free cash flow yield
- -10.69%
Fundamentals
- Revenue
- $27.59M
- Net income
- -$207.90M
- EPS, diluted
- -$3.41
- Free cash flow
- -$180.68M
- Book value per share
- $5.23
- Diluted shares
- 66M
Trading
- Next earnings
- Jan 11, 2027 (estimated, before the open)
- Previous close
- $27.76
- Open
- $27.51
- Day's range
- $26.14 – $27.70
- Volume
- 501,225
- Average volume (20 days)
- 1,384,656
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.62
- 52-week range
- $22.05 – $40.22
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 53.2%
- Relative volume
- 0.52×
- WACC
- 13.0%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | STOK | S&P 500 | Difference | STOK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.5% | -2.7% | +11.2 pts | ||
| 3 months | -20.5% | -1.7% | −18.8 pts | ||
| Year to date | -17.5% | +11.9% | −29.3 pts | ||
| 1 year | +4.3% | +12.0% | −7.7 pts | ||
| 3 years | +515.0% | +78.2% | +436.8 pts | +83.2% | +21.2% |
| 5 years | -7.8% | +73.2% | −81.1 pts | -1.6% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Stoke Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
About Stoke Therapeutics
Pharmaceutical Preparations
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company that develops antisense oligonucleotide medicines to address the genetic causes of severe diseases. Utilizing its Targeted Augmentation of Nuclear Gene Output platform, the company restores protein expression in haploinsufficiency disorders affecting the central nervous system and the eye. Its lead product candidate is zorevunersen, an investigational treatment for Dravet syndrome, and its pipeline includes STK-002 for autosomal dominant optic atrophy alongside preclinical research programs. Stoke Therapeutics develops these therapies for patients with rare genetic conditions and collaborates with biopharmaceutical partners including Biogen and Acadia Pharmaceuticals.
Company profile, executives and historyStoke Therapeutics stock: common questions
What is Stoke Therapeutics's stock price?
STOK closed at $26.20 on Nov 12, 2026, down 5.62% on the day. Over the past 52 weeks it traded between $22.05 and $40.22.
What is Stoke Therapeutics's market cap?
Stoke Therapeutics was worth $1.69B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is STOK's P/E ratio?
Stoke Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.41), so it has no meaningful P/E ratio.
How much revenue does Stoke Therapeutics make?
Stoke Therapeutics reported revenue of $27.59M for the twelve months to Jun 30, 2026, down 86.2% from a year earlier.
Does Stoke Therapeutics pay a dividend?
No. Stoke Therapeutics has not paid a cash dividend over the last twelve months.
When does Stoke Therapeutics report earnings next?
Stoke Therapeutics is expected to report Q4 FY2026 results on Jan 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has STOK stock performed over the past year?
Including dividends, STOK returned +4.3% over the past year, against +12.0% for the S&P 500.
How many STOK shares are sold short?
11M shares were sold short at the latest FINRA report, 28.45% of the float, or 6.8 days of average trading volume.
Who are Stoke Therapeutics's competitors?
Companies most similar to Stoke Therapeutics by business, industry and size include QURE, WVE, PRQR, NAMS, KROS.
See a number that looks wrong?